Skip to main content

Table 2 Best response according to RECIST in both groups

From: Customized chemotherapy based on epidermal growth factor receptormutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial

 

Gefitinib (N = 22)

VNR or GEM (N = 32)

Complete response

0

0

Partial response

10 (45.5%)

6 (18.8%)

Stable disease

9 (40.9%)

12 (37.5%)

Progressive disease

1 (4.5%)

6 (18.8%)

Not evaluable

2 (9.1%)

8 (25.0%)

  1. GEM: gemcitabine; RECIST: Response Evaluation Criteria in Solid Tumors; VNR: vinorelbine.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us